Complement sensing of nanoparticles and nanomedicines

ACS Symposium Series

Volumn 1113, Issue , 2012, Pages 365-382

  Wibroe, Peter P ^a,b   Moghimi, S Moein ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; DRUG DELIVERY;

ACTIVE PHARMACEUTICAL INGREDIENTS; COMPLEMENT ACTIVATIONS; INNATE IMMUNE SYSTEMS; INTRAVENOUS INJECTIONS; PHYSICOCHEMICAL PARAMETERS; PHYSICOCHEMICAL PROPERTY; RETICULOENDOTHELIAL SYSTEMS; STATE-OF-THE-ART APPROACH;

NANOPARTICLES;

EID: 84905278167     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2012-1113.ch014     Document Type: Article

References (48)

1. Moghimi, S. M.; Peer, D.; Langer, R. Reshaping the future of nanopharmaceuticals: Ad iudicium. ACS Nano 2011, 5, 8454-8458.
2. Shi, J.; Xiao, Z.; Kamaly, N.; Farokhzad, O. C. Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation. Acc. Chem. Res. 2011, 44, 1123-1134.
3. Moghimi, S. M.; Hunter, A. C.; Andresen, T. L. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 481-503.
4. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 2001, 53, 283-318.
5. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19, 311-330.
6. Hamad, I.; Al-Hanbali, O.; Hunter, A. C.; Rutt, K. J.; Andresen, T. L.; Moghimi, S. M. Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere-Serum Interface Implications for Stealth Nanoparticle Engineering. ACS Nano 2010, 4, 6629-6638.
7. Hamad, I.; Hunter, A. C.; Rutt, K. J.; Liu, Z.; Dai, H.; Moghimi, S. M. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 2008, 45, 3797-3803.
8. Moghimi, S. M.; Hunter, A. C. Complement monitoring of carbon nanotubes. Nat. Nanotechnol. 2010, 5, 382.
9. Andersen, A. J.; Wibroe, P. P.; Moghimi, S. M. Perspectives on carbon nanotube-mediated adverse immune effects. Adv. Drug Delivery Rev. 2012, http://dx.doi.org/10.1016/j.addr.2012.05.005.
10. Ricklin, D.; Hajishengallis, G.; Yang, K.; Lambris, J. D. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11, 785-797.
11. Moghimi, S. M.; Andersen, A. J.; Hashemi, S. H.; Lettiero, B.; Ahmadvand, D.; Hunter, A. C.; Andresen, T. L.; Moghimi, S. M. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead. J. Controlled Release 2010, 146, 175-181.
12. Moghimi, S. M.; Wibroe, P. P.; Helvig, S. Y.; Farhangrazi, S.; Hunter, A. C. Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. Adv. Drug Delivery Rev. 2012, http://dx.doi.org/10.1016/j.addr.2012.05.010.
13. Moghimi, S. M.; Andersen, A. J.; Ahmadvand, D.; Wibroe, P. P.; Andresen, T. L.; Hunter, A. C. Material properties in complement activation. Adv. Drug Delivery Rev. 2011, 63, 1000-1007.
14. Lambris, J. D.; Ricklin, D.; Geisbrecht, B. V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6, 132-142.
15. Kemper, C.; Atkinson, J. P.; Hourcade, D. E. Properdin: emerging roles of a pattern-recognition molecule. Annu. Rev. Immunol. 2010, 28, 131-155.
16. Fearon, D. T.; Austen, K. F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 1975, 142, 856-863.
17. Bradley, D. V.; Wong, K.; Serrano, K.; Chonn, A.; Devine, D. Liposomecomplement interactions in rat serum: Implications for liposome survival studies. Biochim. Biophys. Acta 1994, 1191, 43-51.
18. Pedersen, M. B.; Zhou, X.; Larsen, E. K. U.; Sorensen, U. S.; Kjems, J.; Nygaard, J. V.; Nyengaard, J. R.; Meyer, R. L.; Bosen, T.; Vorup-Jensen, T. Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation. J. Immunol. 2010, 184, 1931-1945.
19. Lunqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A. Nanoparticle size and surface properties determinethe protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 14265-14270.
20. Perkins, S. J.; Nealis, A. S.; Sutton, B. J.; Feinstein, A. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modeling. A possible mechanism for complement activation. J. Mol. Biol. 1991, 221, 1345-1366.
21. Roux, K. H. Immunoglobulin structure and function as revealed by electron microscopy. Int. Arch. Allergy Immunol. 1999, 120, 85-99.
22. Janssen, B. J.; Christodoulidou, A.; McCarthy, A.; Lambris, J. D.; Gros, P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444, 213-216.
23. Chonn, A.; Cullis, P.; Devine, D. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991, 146, 4234-4241.
24. Bradley, A. J.; Brooks, D. E.; Norris-Jones, R.; Devine, D. V. C1q binding to liposomes is charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1Qa chain in a sequence independent manner. Biochim. Biophys. Acta 1999, 1418, 19-30.
25. Devine, D. V.; Marjan, J. M. J. The role of immunoproteins in the survival of liposomes in the circulation. Crit. Rev. Ther. Drug Carrier Syst. 1997, 14, 105-131.
26. Moghimi, S. M.; Hunter, A. C. Recognition of macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res. 2001, 18, 1-8.
27. Bradley, A. J.; Maurer-Spurej, E.; Brooks, D. E.; Devine, D. V. Unusual electrostatic effect on binding of C1q to anionic liposomes: role of anionic phospholipids domain and their line tension. Biochemistry 1999, 38, 8112-8123.
28. Sou, K.; Tsuchida, E. Electrostatic interactions and complement activation on the surface of phospholipid vesicle containing acidic lipids: Effect of the structure of acidic groups. Biochim. Biophys. Acta 2008, 1778, 1035-1041.
29. Merkel, O. M.; Urbanics, R.; Bedocs, P.; Rozsnyay, Z.; Rosivall, L.; Toth, M.; Kissel, T.; Szebeni, J. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-grafted-poly(ethylene glycol) block copolymers. Biomaterials 2011, 32, 4936-4942.
30. Moghimi, S. M.; Hamad, I.; Andresen, T. L.; Jorgensen, K.; Szebeni, J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 2006, 20, 2591-2593.
31. Mizrahy, S.; Raz, S. R.; Hasgaard, M.; Liu, H.; Soffer-Tsur, N.; Cohen, K.; Dvash, R.; Landsman-Milo, D.; Bremer, M. G. E. G.; Moghimi, S. M.; Peer, D. Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J. Controlled Release. 2011, 156, 231-238.
32. Al-Hanbali, O.; Rutt, K. J.; Sarker, D. K.; Hunter, A. C.; Moghimi, S. M. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J. Nanosci. Nanotechnol. 2006, 6, 3126-3133.
33. Hamad, I.; Hunter, A. C.; Szebeni, J.; Moghimi, S. M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 2008, 46, 225-232.
34. Moghimi, S. M.; Hunter, A. C.; Dadswell, C. M.; Savay, S.; Alving, C. R.; Szebeni, J. Causative factors behinf poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta-Mol. Basis Dis. 2004, 1689, 103-113.
35. Weiszhar, Z.; Czucz, J.; Revesz, C.; Rosivall, L.; Szebeni, J; Rozsnyay, Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. Sci. 2012, 45, 492-498.
36. Lettiero, B.; Andersen, A. J.; Hunter, A. C.; Moghimi, S. M. Complement system and the brain: selected pathologies and avenues toward engineering of neurological nanomedicines. J. Control. Rel. 2012, 161, 283-289.
37. Wu, Y-Q.; Qu, H. C.; Sfyroera, G.; Tzekou, A.; Kay, B. K.; Nilsson, B.; Ekdahl, K. N.; Ricklin, D.; Lambris, J. D. Protection of nonself surfaces from complement attack by factor H-binding peptides: Implications for therapeutic medicine. J. Immunol. 2011, 186, 4269-4277.
38. Harboe, M.; Thorgersen, E. B.; Mollnes, T. E. Advances in assay of complement function and activation. Adv. Drug Delivery Rev. 2011, 63, 976-987.
39. Szebeni, J.; Baranyi, L.; Savay, S.; Milosevits, J.; Bodo, M.; Bunger, R.; Alving, C. R. The interaction of liposomes with the complement system: In vitro and in vivo assays. Method Enzymol. 2003, 373, 136-154.
40. Meerasa, A.; Huang, J. G.; Gu, F. X. CH50: A revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction. Curr. Drug Delivery 2011, 8, 290-298.
41. Arima, Y.; Toda, M.; Iwata, H. Surface Plasmon resonance in monitoring of complement activation on biomaterials. Adv. Drug Delivery Rev. 2011, 63, 988-999.
42. Sellborn, A.; Andersson, M.; Hedlund, J.; Andersson, J.; Berglin, M.; Elwing, H. Immune complement activation on polystyrene and silicon dioxide surfaces Impact of reversible IgG adsorption. Mol. Immunol. 2005, 42, 569-574.
43. Andersson, M.; Andersson, J.; Sellborn, A.; Berglin, M.; Nilsson, B.; Elwing, H. Quartz crystal microbalance-with dissipation monitoring (QCM-D) for real-time measurements of blood coagulation density and immune complement activation on artificial surfaces. Biosens. Bioelectron. 2005, 21, 79-86.
44. Moghimi, S. M.; Hamad, I. Liposome-mediated triggering of complement cascade. J. Liposome Res. 2008, 18, 195-209.
45. Szebeni, J.; Muggia, F.; Gabizon, A.; Barenholz, Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Delivery Rev. 2011, 63, 1020-1030.
46. Anderson, N.; Anderson, N. The human plasma proteome-History, character, and diagnostic prospects. Mol. Cell Proteomic. 2002, 1, 845-867.
47. Pareek, C.; Smoczynski, R.; Tretyn, A. Sequencing technologies and genome sequencing. J. Appl. Genet. 2011, 52, 413-435.
48. Mitragotri, S.; Lahann, J. Physical approaches to biomaterial design. Nat. Mat. 2009, 8, 15-23.